RxDoctor Payments Data
★ My doctorsLook up a doctor →

Thomas Reynolds, MD

Medical Oncology · Montebello, CANPI 1457398471

Payments from drug & device makers

$14,517in general payments, 2019–2025

Across 694 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$931
  • Bristol Myers Squibb$890
  • Pfizer$782
  • Johnson & Johnson$764
  • Merck$595
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,97389%
  • Education$3482%
  • Other$1,1968%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis65$1,905
E.r. Squibb & Sons, L.L.C.64$931
Bristol Myers Squibb44$890
Pfizer48$782
Johnson & Johnson52$764
Merck31$595
AstraZeneca(2 entities)19$583
Bayer19$416
Incyte Corporation17$409
Seagen Inc.19$407
Astellas Pharma US Inc19$386
Amgen15$384
Takeda Pharmaceuticals U.S.A., Inc.13$371
Eisai Inc.15$322
Pharmacyclics LLC, An Abbvie Company13$308
Daiichi Sankyo Inc.14$269
Sanofi15$262
Array Biopharma Inc13$240
Boehringer Ingelheim13$237
GSK9$228
Lilly USA, LLC11$222
AbbVie8$207
Gilead(2 entities)9$189
Puma Biotechnology, Inc.9$186
Regeneron Healthcare Solutions, Inc.7$183
Genentech USA, Inc.8$179
Beigene USA, Inc.5$151
Rigel Pharmaceuticals, Inc.7$141
Karyopharm Therapeutics Inc.4$135
EMD Serono, Inc.5$122
Taiho Oncology, Inc.6$118
Exelixis Inc.6$116
Agios Pharmaceuticals, Inc.5$112
Sobi, Inc4$107
GE HealthCare5$103
Dova Pharmaceuticals4$93
Deciphera Pharmaceuticals Inc.5$93
EUSA Pharma (US) LLC4$74
AVEO Pharmaceuticals, Inc.3$68
Jazz Pharmaceuticals Inc.3$68
Blueprint Medicines Corporation3$67
Clovis Oncology, Inc.3$65
Tesaro, Inc.2$63
Foundation Medicine, Inc.3$60
Legend Biotech USA Inc.3$58
Global Blood Therapeutics, Inc.3$51
Secura Bio, Inc.5$50
Dendreon Pharmaceuticals LLC2$47
Teva Pharmaceuticals USA, Inc.2$45
Epizyme, Inc.2$44
Adaptive Biotechnologies Corporation2$41
Ipsen Biopharmaceuticals, Inc2$41
G1 Therapeutics, Inc.2$40
Myovant Sciences Inc.2$40
Sanofi-aventis U.S. LLC2$38
Boston Scientific1$37
Progenics Pharmaceuticals, Inc.2$33
Stemline Therapeutics Inc.2$32
Tempus AI, Inc1$29
Genmab U.S., Inc.1$28

How this compares

$14,517 in reported general payments places this provider in the 40th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$69,514
Medicare patients
113
Services billed
3,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Montebello

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →